Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
Date:11/9/2011

nse (except for certain Asian Pacific countries) to Zerenex (ferric citrate) from Panion & BF Biotech, Inc. The Japanese rights are sublicensed by Keryx to Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for Zerenex (ferric citrate), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
3. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
4. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
7. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
8. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
10. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
11. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 6, 2015  Approximately 1% of the population inherits ... chromosomes. These individuals are three times more likely to ... one of the nation,s leading medical journals by researchers ... Photo - http://photos.prnewswire.com/prnh/20150706/230685 ... causes roseola (also known as "sixth disease") and occasional ...
(Date:7/6/2015)... 6, 2015 Navitas, a leading Regulatory Service provider, today announced ... hub in Bogota, Colombia . Navitas, expansion into ... provided by Colombia , the third largest economy in ... Logo - http://photos.prnewswire.com/prnh/20150703/228239LOGO ... based clients to communicate with Navitas regulatory professionals in close to or ...
(Date:7/3/2015)... , ... July 03, 2015 , ... ... by Fortune 500 companies and professional service industries alike-- typically known for its ... clients laugh, honor a good cause and break from their day jobs. , ...
(Date:7/3/2015)... 3, 2015 Forskere ... 2015 på  http://www.openinnovationinscience.at om efteruddannelsesprogrammet "Lab ... sted i Wien .  ... internationale forskere og videnskabsmænd foretaget af Ludwig ... udfordringer for sundhedsvidenskaben manglen på incitamenter til ...
Breaking Biology Technology:Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3Navitas Launches Latin American Regulatory Operations Hub in Bogota, Colombia 2Navitas Launches Latin American Regulatory Operations Hub in Bogota, Colombia 3The Alexander Group Declares Their Independence with a Bit of Levity 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3
... Wis. - BEST BioDiesel, LLC has received ... Natural Resources for an eight million gallon fuel production ... BioDiesel Cashton and be a wholly owned subsidiary of BEST ... located on a six-acre site in the Cashton Green Energy ...
... Partners Midwest, a venture capital arm of Boston's Peak ... initial goal for raising capital and is ready to scout ... fund, which was to be capped at $50 million, has ... an initial close, according to Michael McNally, chairman and CEO ...
... West Allis, Wis. - In the wake of financial ... Merge Healthcare has added another new face to ... through Georgia. , ,Merge announced the hiring of Greg Wilson, ... . of Atlanta, as its new vice president of finance. ...
Cached Biology Technology:Avolte Venture Partners reaches capital goal 2
(Date:6/24/2015)... , June 24, 2015  Synaptics Inc. ... human interface solutions, today announced that Sharp has ... provide secure authentication for its latest flagship smartphone ... more than 200 million shipments of its fingerprint ... reinforces Synaptics, strength, scalability and leadership in the ...
(Date:6/23/2015)...   MedNet Solutions , an innovative SaaS-based ... of clinical research, is pleased to announce that ... company,s intuitive, flexible and affordable cloud-based eClinical technology ... Award by the American Business Awards (SM) ... The American Business Awards are considered the nation,s ...
(Date:6/23/2015)... June 23, 2015  Crossmatch™, a leading ... today announced enhanced functionality of its DigitalPersona ... The enhancements build on the native flexibility ... Altus platform and provide expanded mobile credential ... In today,s environment of increasing cyber-attacks and ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
... Rochelle, NY, January 23, 2013-The U.S. Food and Drug Administration ... of medical devices to ensure that any sex differences in ... authors from the FDA report the results of a study ... in PAS in Journal of Women,s Health, a peer-reviewed publication ...
... NEW YORK, NY (January 22, 2014) Columbia University ... matrix metalloproteinase-9 (MMP-9), that appears to play a major ... (ALS), also known as Lou Gehrig,s disease. The findings, ... motor neurons are affected by the disease and identify ...
... This 2014 FASEB Science Research Conference focuses on ... mechanisms controlling normal and abnormal functions of muscle-resident ... and muscle degenerative disease. Eight plenary ... the following major themes: transcriptional and posttranscriptional regulation ...
Cached Biology News:Study identifies gene tied to motor neuron loss in ALS 2Study identifies gene tied to motor neuron loss in ALS 3
Glutamate Receptor 5/1a...
... Rabbit monoclonal [EP282Y] to ... for all tested applications). ... peptide corresponding to residues in ... synthetase. Entrez ...
Shh Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Anti-human C5/C5b, Clone 568, Monoclonal Antibody...
Biology Products: